Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA lipid nanoparticle
- Development stage
- Preclinical
- Lead developer
- Nottingham Trent University
- Modality
- Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
The **anti-BCMA lipid nanoparticle** (also referred to as MMAF-Lp-Ab) is an experimental targeted drug delivery system designed for the treatment of multiple myeloma. Developed by researchers at Nottingham Trent University and Royal Derby Hospital, the therapeutic consists of liposomes (lipid nanoparticles) encapsulating the cytotoxic tubulin inhibitor monomethyl auristatin F (MMAF) and conjugated to anti-B-cell maturation antigen (BCMA) antibodies on their surface. This formulation is designed to selectively target and internalize into BCMA-expressing myeloma cells, delivering the MMAF payload directly to the tumor cells to induce cytotoxicity while minimizing off-target side effects.
- Other names
- MMAF-Lp-Abanti-BCMA lipid-based nanoparticleanti-BCMA liposome encapsulating MMAFanti-BCMA MMAF liposomeanti-BCMA targeted lipid nanoparticleanti-BCMA targeted liposome
02
Targets
TUBB (Tubulin (alpha and beta subunits))BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA lipid nanoparticle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA lipid nanoparticle.